INTRODUCTION
Bipolar disorder is a chronic disease characterized by periods of mania or hypomania (episodes of elevated moods, extreme irritability, decreased sleep, and increased energy), depression (overwhelming feelings of sadness, anhedonia, suicidal thoughts) or a combination of both (named as mixed state). The exact cause of the condition is unknown, but genetic, physiological, neurological, psychosocial, and environmental factors may be involved. According to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, the diagnosis of bipolar type I requires the presence or the history of at least one manic or mixed episode, whereas bipolar disorder type II differs from type I only by the presence of hypomania but no manic episodes [1] .
The prevalence of bipolar I disorder in Italy is estimated to be approximately 1-2%, even if the true prevalence is likely to be much higher because it is frequently under-diagnosed, largely due to the fact that it is difficult to diagnose correctly [2] . Because bipolar disorder is one of the leading causes of disability, especially in active populations, it represents an important economic burden on society [3] . A study evaluating the cost of bipolar disorder in the UK has estimated a cost of £198.7 million per year, with hospitalization accounting for the largest component of direct costs [4] .
Mixed episodes are a common feature of bipolar I disorder and they are associated with more severe symptoms and outcomes [5, 6] ; moreover, this type of episode tends to last longer than manic and depressive episodes [7] and is more commonly associated with substance abuse, anxiety disorders, and suicidality [8] [9] [10] . Treatment of bipolar mixed states is often challenging as response is usually poorer than in manic or depressive episodes [11] and involves the use of lithium (Li), sodium valproate (VPA), and second-generation antipsychotics (SGAs) [12] . Currently, the best evidence for efficacy as monotherapy for the acute treatment of mixed state is provided for anticonvulsants followed by the atypical antipsychotics: aripripazole, asenapine (ASE), paliperidone, and ziprasidone [13] . There was also very strong evidence for the use of olanzapine (OLA) as monotherapy or as addon to Li or VPA [13] .
In 2013, the first meta-analysis of the efficacy of SGAs in mixed episodes was published, suggesting that some of these drugs are effective in reducing not only manic but also depressive symptoms in patients with mixed episodes [14] . SGAs, particularly ASE, OLA, aripriprazole, paliperidone, risperidone, and ziprasidone were reported to be efficacious on maniac symptoms of mixed episodes, while ASE and OLA also appear to be moderately efficacious in treating depressive symptoms of mixed episodes [14, 15] .
ASE is a new SGA developed and approved in the USA for the acute treatment, as monotherapy or adjunctive therapy with either Li or VPA, of manic or mixed episodes associated with bipolar I disorder. Whether used as monotherapy or as adjunctive therapy with Li or VPA, the use of ASE in responding patients is generally recommended by the Food and Drug Administration to be continued beyond the acute response [16] . In Europe, in September 2010, the European Medicines Agency has authorized the marketing of this molecule for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults.
Focusing on mixed episode patients, Azorin et al. [17] assessed the efficacy of ASE using post hoc analyses on pooled data from two identical 3-week, randomized, double-blind, placeboand OLA-controlled trials [18, 19] and their 9-week double-blind, OLA-controlled extension study [20] . At week three, ASE was found to be significantly superior to both placebo and OLA both on manic and depressive symptoms improving Montgomery-Å sberg Depression Rating Scale (MADRS) and Young Mania Rating Scale (YMRS) scores. At week 12, further decrease in YMRS and in MADRS total scores was observed with ASE, although not reaching a statistically significant difference.
Although no statistically significant difference was observed between ASE and OLA in composite response rate or mean reduction on either score, these findings suggest a potential difference in the way the two drugs work in mixed episodes.
Even though cost-effectiveness of different SGAs in the treatment of patients experiencing a manic episode associated with bipolar I disorder has been studied in numerous analyses and in different contexts [21] [22] [23] [24] [25] [26] , only a few studies [27, 28] have explored the role of these drugs in patients with mixed episodes.
The current study evaluates from an Italian National Health Service (NHS) perspective, the cost-effectiveness of ASE compared to OLA in the treatment of patients experiencing mixed episodes associated with bipolar I disorder.
Comparison against SGAs was only possible
with OLA due to lack of randomized studies comparing efficacy of ASE versus other antipsychotics in the treatment of the subpopulation with mixed episodes. Furthermore, OLA was the best comparator based on proven efficacy and market-share [13] .
METHODS
The analysis in this article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
Model Introduction
The pharmacoeconomic model was developed to simulate the management of Italian bipolar I patients with mixed episodes over a five-year time horizon by combining clinical parameters with resource utilization.
An expert panel, composed of five psychiatrists from different Italian regions and two health economists from an independent agency, was responsible for adapting a model developed by Sawyer et al. [27] from the UK into an Italian perspective.
Efficacy was informed by a post hoc analysis of two short-term clinical trials, with response measured as a composite MADRS and YMRS [17] . Probabilities of discontinuation and relapse to manic, mixed, and depressive episodes were sourced from published meta-analyses [29, 30] .
The primary outcome measure of the economic evaluation is the incremental costeffectiveness ratio (ICER), where effectiveness is measured in terms of quality-adjusted life years (QALYs) gained.
Because costs were considered from the Italian NHS perspective, only direct medical costs, expressed in Euro, could be evaluated.
The pharmacoeconomic model was developed using Microsoft Office Excel 2007 (Microsoft Corporation, Albuquerque, NM, USA) software.
Description of Model
The model comprises an acute phase and a maintenance phase. The acute phase ( Fig. 1 were sourced from a systematic review and network meta-analysis by Soares-Weiser et al. [30] . As ASE was not available in this review, it was assumed that the annual risk of relapse for ASE was the same as for OLA. Similarly, as no data were available on the efficacy of combination therapies in relapse prevention, it was assumed that risk of relapse was related to the last added treatment.
Since probabilities of relapse from SoaresWeiser et al. [30] were stratified by manic/mixed or depressive episode, the model needed a further breakdown between patients experiencing a recurrent manic episode versus a recurrent mixed episode. For this reason, the authors applied the probability of a relapse split between mania and mixed episodes from the study by Vieta and colleagues (53.3% mania and 46.7% mixed) [33] .
Treatment discontinuation in the model is defined as patients discontinuing their antipsychotic treatment and moving on to a ''minimal treatment'', which was assumed to be VPA alone for 50% of patients and Li alone for the other 50%. As in the UK model, probability of discontinuing treatment with the initial drug during periods of disease stability was calculated by applying a risk ratio from a published metaanalysis of clinical trials [34] to an underlying baseline probability of discontinuing on placebo. The placebo discontinuation rates are based on a published discrete-event simulation model for patients with acute bipolar depression [29] . Again, as ASE-treatment discontinuation risk was not available in the meta-analysis, it was assumed that the treatment discontinuation probability for ASE was the same as for OLA (Table 1) .
Patients who failed to respond to the 1st-, 2nd-, and 3rd-line treatments in the acute phase enter the maintenance phase as non-responders and on triple therapy (AA ? VPA ? Li). Due to lack of data, the authors have assumed a 35% per cycle probability of reaching the subacute health state and varied the base case probability in a sensitivity analysis from 0% to 100%.
The subacute health state was implemented in the model as a temporary tunnel state, through which responding patients must transition before achieving stable euthymia.
From this temporary tunnel state, a monthly probability of achieving euthymia was estimated to be 60% based on expert opinion.
Also this probability has been tested by the authors with a sensitivity analysis from 0% to 100%. The mortality risk, stratified by causes (suicide and non-suicide), was calculated starting from the interim life tables for Italy [35] and applying the general population annual risk of suicide from the same source. Finally, the authors applied standardized mortality ratios for suicide (11.53) and nonsuicide (1.69) retrieved from Angst et al. [36] to define the mortality risk among patients with bipolar I disorder.
Adverse Event
The model incorporates two common adverse events due to antipsychotic medication: weight gain and extrapyramidal symptoms (EPS), whose incidences, that are different according to drug regimen, were retrieved from several trials [17, 33, 37, 38] . Weight gain is associated with all bipolar disorder drugs; so, this adverse event was associated with all drugs. For combination therapies, the incidence of weight gain is set to equal that of the drug Table 1 .
Utilities
Utility values for the model health states and adverse events were derived from the UK model [24] , except for inpatient and outpatient mixed episodes utilities; since no data were available in literature, the authors agreed to set the same values as those set for mania ( Table 2 ).
The utility values of the general population applied in the model were converted to multipliers using the formulae of Ara and Brazier [39] , which take into account the ageand gender-distribution relative to the study population.
In order to derive the condition-specific utility values for the model health states and adverse events, a multiplicative approach was used considering multipliers defined according to different health states and adverse events.
Costs and Resource Utilization
This model considered only direct medical costs including those associated with drug acquisition, general practitioner (GP) visits and specialist visits, examinations, and hospitalizations. This model is set in the Italian NHS perspective. Therefore, only the costs directly reimbursed by the NHS were considered. Since a 5-year time horizon was set, a discounting of 0.035% was applied.
Drug costs were calculated based on prices listed on the Italian Drug Agency website [40] .
For generic drugs, the authors considered prices reimbursed by the NHS, whereas for ASE, the only branded drug, the authors considered the public price applying a discount for NHS (12.5% for drugs between €103.29 and €154.94) after VAT. Treatment doses used in the analysis were the weighted average of the daily doses found in literature. The unit costs per mg, daily doses (mg), and daily costs for the drugs used in this model are reported in Table 3 . In order to test the dosages applied in the model, the authors developed a scenario analysis adopting the recommended daily doses from the summary of product characteristics (SPCs) for both the acute phase and the maintenance phase (Table 3) .
Resource utilization was differentiated according to drug regimen and for the acute and maintenance phases, and it was assessed to reflect the Italian standard clinical practice. Full blood count, liver panel, blood urea, creatinine, thyroid function (i.e., thyroidstimulating hormone), serum Li Table 4 and unit costs were retrieved from the TUC 2014. The authors assumed that the cost for the stable health state is the baseline cost and any relapse event represents an additional cost.
As mentioned before, the main adverse events for patients on treatment for bipolar I disorder are weight gain and EPS. The weight gain costs for the acute phase were a dietician Table 4 Management breakdown by Soares-Weiser et al. [30] , from expert opinion and costs for healthcare services Based on input from the expert panel, the following analyses were developed:
• Scenario analysis on different drugs doses;
• Scenario analysis on different episode management breakdown;
• Sensitivity analysis on transition probability from non-responder to subacute state;
• Sensitivity analysis on transition probability from subacute state to stable state. Furthermore, a probabilistic sensitivity analysis (PSA), in which all model parameters have been varied simultaneously, was also performed. (Table 5 ). An incremental gain of 0.0106 QALYs is observed when the impact of adverse events is excluded from quality of life calculations. Also on this outcome, ASE dominates OLA in our cost-effectiveness model (Table 5) . When only the acute phase is considered (Table 5) , referring to the first 9 weeks of treatment after the mixed episode, ASE generates greater benefits than OLA (0.0045 more QALYs and 0.0041 more QALYs when the impact of adverse events is excluded) at lower costs (€1,065.4 less). This result indicates that the incremental QALYs and savings are derived largely from the earlier response to treatment during the acute phase. Table 6 describes the results of the scenario analysis on different drug doses in which the average doses derived from clinical studies used in the base case were changed to the daily doses from the SPCs (see Table 3 ).
RESULTS

Base Case Analysis
Scenario Analyses
Compared to OLA, also here ASE dominates OLA, with a lower incremental total cost (€1,173.7 less than OLA), with respect to the base case analysis (€461.3 less than OLA) thanks to savings in the treatment costs (€422.2 vs.
€1,134.5, respectively).
The results of the scenario analysis on the episodes management breakdown as derived from the experts' opinions rather than the one used in the base case analysis (see Table 4 ) are described in Table 6 . Costs generated by ASE and OLA are slightly lower than the ones of the base case analysis (€31,219.7 and €31,528.4, respectively) due to savings in health state costs.
The consistency of results between the base case and the two scenario analyses supports the robustness of the model.
Sensitivity Analyses
A sensitivity analysis on the probability of changing health state from non-responders to subacute health state during the maintenance phase was performed. In the base case analysis, this probability was set at 35% per cycle, while the sensitivity analyses used a probability of 0% and 100%. Results appeared sensitive to variations in this parameter, but ASE remained AEs adverse events, ASE asenapine, OLA olanzapine, QALYs quality-adjusted life years, w/ with, w/o without AEs adverse events, ASE asenapine, OLA olanzapine, QALYs quality-adjusted life years, w/ with, w/o without dominant over OLA throughout the entire range tested by the sensitivity analysis (Table 7) .
Another sensitivity analysis was performed on the probability of reaching the stable health state from the subacute health state. In this analysis the probability was changed from the 60% in the base case analysis to a range from 0% to 100%. Also in this case ASE remained dominant over OLA, similarly to the results obtained in the base case analysis (Table 7) .
Probabilistic Sensitivity Analyses
In the PSA, the probabilities of response, relapse, discontinuation, and death, the health state utility values and the unit costs were probabilistically sampled 1,000 times generating 1,000 samples. samples that should need money investment in order to achieve additional QALYs by using ASE. In this study, due to the lack of official willingness to pay threshold in Italy, we decided to use an ICER threshold of €30,000 per QALY, slightly lower than the one recognized by the National Institute for Health and Care
Excellence (NICE; £20,000-30,000) [42] .
Being so, with a willingness-to-pay threshold set to €30,000 per QALY, treatment of patients is necessary to establish priorities in the allocation of resources in a specific therapeutic area. Indeed, they supply decision makers within healthcare systems with useful tools to make more rational and effective decisions.
The main study limitation concerns the lack of publications regarding ASE treatment of bipolar I type with mixed episode patients, and adequate comparative data for other SGAs in acute phase. In previous meta-analysis [14, 44] only post hoc analyses on pooled data from clinical trials by McIntyre [18] [19] [20] were found comparing ASE and OLA in mixed episodes. Therefore, the authors of this pharmacoeconomic study, similarly to the authors of the previous pharmacoeconomic study performed in the UK [27] , used the post hoc analyses by Azorin et al. [17] to derive the efficacy and safety of treatments. The model was validated by expert opinions.
Whilst important basic values, such as efficacy and safety of OLA and ASE, were available from these post hoc analyses, evidence for other important parameters, i.e. efficacy of adjunctive therapies, longer-term efficacy of SGAs in relapse prevention, was not available. Therefore, to minimize possible bias, treatment efficacy of combination treatments was assumed to be equal between ASE and OLA, and assumption was made that, during maintenance, in mixed episodes patients efficacy in relapse prevention was similar for both treatments arms.
Model robustness was tested using both deterministic and probabilistic sensitivity analyses; results proved the model reliability.
Another possible limitation could be that only EPS and weight gain has been considered among possible SGAs adverse events.
Nevertheless, since ASE showed a better safety profile compared to OLA with regard to metabolic effects including dyslipidemia and type 2 diabetes mellitus [45] , the impact of other adverse events could possibly generate a better performance for ASE.
CONCLUSION
Results from this study suggest that the management of bipolar I patients with mixed episodes using ASE as alternative to OLA can lead to cost savings for Italian NHS and improve patients' quality of life. Future researches specifically developed for this subset of patients are needed to fill the gap of information that are required by the costeffectiveness model and to permit the comparison of ASE with other SGAs.
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